Xatmep™ (methotrexate) – New drug approval
April 26, 2017– Silvergate Pharmaceuticals announced the FDA approval of Xatmep (methotrexate) oral solution for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen and for the management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
Top